Review
[Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy]
[Article in
Polish]
Affiliations
- PMID: 16479834
Item in Clipboard
Review
[Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy]
[Article in
Polish]
Pol Arch Med Wewn.
2005 May.
No abstract available
Similar articles
-
Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.Oncotarget. 2014 Nov 15;5(21):10407-20. doi: 10.18632/oncotarget.2090. Oncotarget. 2014. PMID: 25431951 Free PMC article.
-
PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment.Cancer Chemother Pharmacol. 2008 Apr;61(4):713-6. doi: 10.1007/s00280-007-0507-7. Epub 2007 Jun 5. Cancer Chemother Pharmacol. 2008. PMID: 17549478
-
Development of Löffler's endocarditis in FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome despite continuous imatinib mesylate therapy and continuous complete remission.Am J Hematol. 2010 Apr;85(4):296-9. doi: 10.1002/ajh.21635. Am J Hematol. 2010. PMID: 20169542 No abstract available.
-
FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.Verh K Acad Geneeskd Belg. 2005;67(3):169-76. Verh K Acad Geneeskd Belg. 2005. PMID: 16089297 Review.
-
FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.Hematol J. 2004;5 Suppl 3:S133-7. doi: 10.1038/sj.thj.6200439. Hematol J. 2004. PMID: 15190295 Review. No abstract available.